WHWK Whitehawk Therapeutics Inc.

Price (delayed)

$4.43

Market cap

$219.07M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.71

Enterprise value

$184.28M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 0

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is ...

Highlights
WHWK's quick ratio is down by 41% year-on-year but it is up by 11% since the previous quarter
Whitehawk Therapeutics's revenue has plunged by 100% from the previous quarter and by 100% YoY
The company's gross profit has shrunk by 100% QoQ and by 100% YoY

Key stats

What are the main financial stats of WHWK

WHWK stock price

How has the Whitehawk Therapeutics stock price performed over time
Intraday
2.07%
1 week
-7.32%
1 month
6.49%
1 year
162.13%
YTD
83.06%
QTD
28.41%

Financial performance

How have Whitehawk Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$122.7M
Net income
-$115.81M
Gross margin
N/A
Net margin
N/A
Whitehawk Therapeutics's revenue has plunged by 100% from the previous quarter and by 100% YoY
The company's gross profit has shrunk by 100% QoQ and by 100% YoY
The operating income has dropped by 94% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does WHWK's price correlate with its fundamentals

Growth

What is Whitehawk Therapeutics's growth rate over time

Valuation

What is Whitehawk Therapeutics stock price valuation
P/E
N/A
P/B
1.8
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
WHWK's price to book (P/B) is 120% more than its last 4 quarters average of 0.8 and 35% more than its 5-year quarterly average of 1.3
The company's equity fell by 48% YoY and by 15% QoQ
Whitehawk Therapeutics's revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Whitehawk Therapeutics business performance

Dividends

What is WHWK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for WHWK.

Financial health

How did Whitehawk Therapeutics financials performed over time
Whitehawk Therapeutics's total assets has decreased by 46% YoY and by 16% QoQ
WHWK's quick ratio is down by 41% year-on-year but it is up by 11% since the previous quarter
The debt is 100% less than the equity
The company's equity fell by 48% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.